Margaret Brimble, CNZM, FRSNZ, PhD, co-scientific founder of SapVax and Distinguished Professor & Director, Medicinal Chemistry at The University of Auckland, has been awarded the 2018 George and Christine Sosnovsky Award in Cancer Therapy from the Royal Society of Chemistry (United Kingdom). The award, which recognizes outstanding accomplishments in the prevention, control, and cure of cancers using chemotherapy, including gene and immunotherapy, was awarded to Dr. Brimble for her role in developing a novel innovative chemistry platform to generate fully-synthetic, self-adjuvanting cancer vaccines for the treatment of different cancers.

“We are incredibly proud to be working with Dr. Margaret Brimble,” said Baiju Shah, Chief Executive Officer of BioMotiv. “Her innovative contributions to the field of oncology research are highly deserving of this recognition.”

Founded in 2016, SapVax is advancing cancer vaccines developed by Dr. Brimble and colleagues at the University of Auckland in New Zealand.  SapVax has exclusive license to a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines.  The Sapvax team is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.